Research suggests the EndoPredict test may eventually be widely used to help make treatment decisions based on the cancer's risk of coming back in a part of the body away from the breast (distant metastasis) within 10 years after diagnosis.
Knowing if a woman has a high or low risk of early-stage breast cancer coming back might help women and their doctors decide if chemotherapy or other treatments to reduce risk after surgery are needed.
Right now, the EndoPredict test is approved to be used in Europe but not the United States. Sividon, the company that makes the EndoPredict test, has said that it plans to seek U.S. Food and Drug Administration approval for the test.
- Subtype Of
- Genomic tests
- Medical Conditions
- Breast cancer